Johnson & Johnson Research and Development Expenses 2012-2026 | JNJ
Johnson & Johnson annual/quarterly research and development expenses history and growth rate from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Johnson & Johnson research and development expenses for the quarter ending March 31, 2026 were $3.527B, a 9.36% increase year-over-year.
- Johnson & Johnson research and development expenses for the twelve months ending March 31, 2026 were $14.967B, a 11.52% decline year-over-year.
- Johnson & Johnson annual research and development expenses for 2025 were $14.665B, a 14.9% decline from 2024.
- Johnson & Johnson annual research and development expenses for 2024 were $17.232B, a 14.23% increase from 2023.
- Johnson & Johnson annual research and development expenses for 2023 were $15.085B, a 6.72% increase from 2022.
|
Johnson & Johnson Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $14,665 |
| 2024 | $17,232 |
| 2023 | $15,085 |
| 2022 | $14,135 |
| 2021 | $14,277 |
| 2020 | $12,159 |
| 2019 | $11,355 |
| 2018 | $10,775 |
| 2017 | $10,594 |
| 2016 | $9,143 |
| 2015 | $9,046 |
| 2014 | $8,494 |
| 2013 | $8,183 |
| 2012 | $7,665 |
| 2011 | $7,548 |
|
Johnson & Johnson Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $3,527 |
| 2025-12-31 | $4,252 |
| 2025-09-30 | $3,672 |
| 2025-06-30 | $3,516 |
| 2025-03-31 | $3,225 |
| 2024-12-31 | $5,298 |
| 2024-09-30 | $4,952 |
| 2024-06-30 | $3,440 |
| 2024-03-31 | $3,542 |
| 2023-12-31 | $4,480 |
| 2023-09-30 | $3,447 |
| 2023-06-30 | $3,703 |
| 2023-03-31 | $3,455 |
| 2022-12-31 | $3,485 |
| 2022-09-30 | $3,485 |
| 2022-06-30 | $3,703 |
| 2022-03-31 | $3,462 |
| 2021-12-31 | $4,283 |
| 2021-09-30 | $3,422 |
| 2021-06-30 | $3,394 |
| 2021-03-31 | $3,178 |
| 2020-12-31 | $4,032 |
| 2020-09-30 | $2,840 |
| 2020-06-30 | $2,707 |
| 2020-03-31 | $2,580 |
| 2019-12-31 | $3,232 |
| 2019-09-30 | $2,599 |
| 2019-06-30 | $2,666 |
| 2019-03-31 | $2,858 |
| 2018-12-31 | $3,224 |
| 2018-09-30 | $2,508 |
| 2018-06-30 | $2,639 |
| 2018-03-31 | $2,404 |
| 2017-12-31 | $3,643 |
| 2017-09-30 | $2,585 |
| 2017-06-30 | $2,296 |
| 2017-03-31 | $2,070 |
| 2016-12-31 | $2,688 |
| 2016-09-30 | $2,178 |
| 2016-06-30 | $2,264 |
| 2016-03-31 | $2,013 |
| 2015-12-31 | $2,864 |
| 2015-09-30 | $2,154 |
| 2015-06-30 | $2,129 |
| 2015-03-31 | $1,899 |
| 2014-12-31 | $2,635 |
| 2014-09-30 | $2,023 |
| 2014-06-30 | $2,005 |
| 2014-03-31 | $1,831 |
| 2013-12-31 | $2,411 |
| 2013-09-30 | $2,042 |
| 2013-06-30 | $1,946 |
| 2013-03-31 | $1,784 |
| 2012-12-31 | $2,331 |
| 2012-09-30 | $1,923 |
| 2012-06-30 | $1,766 |
| 2012-03-31 | $1,645 |
| 2011-12-31 | $2,155 |
| 2011-09-30 | $1,773 |
| 2011-06-30 | $1,882 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |